Infectious Disease in Palo Alto, CA
3 verified infectious disease doctors in Palo Alto.
Infectious disease physicians diagnose and manage complex infections, including those that are chronic, resistant, or hard to identify.
NPPES tenure ≠ clinical experience. "Years on NPPES" is time since the physician first registered a National Provider Identifier, not time practicing medicine. Verify current license status with the state medical board.
Dr. Kyong-Jin Lee, MD
Infectious Disease
CMS Open Payments· $2,014 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$2,014
Total received
19
Transactions
2
Paying companies
Top paying companies
Among the 3,681 infectious disease doctors we've analyzed, about 83% received any industry payment (median $1,189 among those who did). This doctor's total ranks around the 69th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US infectious disease doctors.
Payments to Kyong-Jin Lee do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Cameron Dowling, MD
Infectious Disease
CMS Open Payments· $2,771 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$2,771
Total received
40
Transactions
6
Paying companies
Top paying companies
Among the 3,681 infectious disease doctors we've analyzed, about 83% received any industry payment (median $1,189 among those who did). This doctor's total ranks around the 75th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US infectious disease doctors.
Payments to Cameron Dowling do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Thomas Meredith, MD
Infectious Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.